The clinical use of carbamazepine in affective disorders. 1988

J C Ballenger
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston 29425-0691.

Carbamazepine, although not widely used in the treatment of affective disorders until the mid-1970s, is now considered an integral part of the pharmacological treatment of affective disorders. The author reviews much of the currently available data on the clinical effects of carbamazepine for both the acute and prophylactic treatment of affectively ill patients. Because of theoretical implications for the use of carbamazepine in affectively ill patients and reports of early success in uncontrolled trials, the first double-blind, placebo-controlled trial of carbamazepine in affective illness was undertaken at the National Institute of Mental Health in 1976. The results of this trial and other controlled and uncontrolled trials form the basis of this review.

UI MeSH Term Description Entries
D008094 Lithium An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER. Lithium-7,Lithium 7
D002220 Carbamazepine A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. Amizepine,Carbamazepine Acetate,Carbamazepine Anhydrous,Carbamazepine Dihydrate,Carbamazepine Hydrochloride,Carbamazepine L-Tartrate (4:1),Carbamazepine Phosphate,Carbamazepine Sulfate (2:1),Carbazepin,Epitol,Finlepsin,Neurotol,Tegretol
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000341 Affective Disorders, Psychotic Disorders in which the essential feature is a severe disturbance in mood (depression, anxiety, elation, and excitement) accompanied by psychotic symptoms such as delusions, hallucinations, gross impairment in reality testing, etc. Depression, Reactive, Psychotic,Mood Disorders, Psychotic,Psychoses, Affective,Psychotic Affective Disorders,Psychotic Mood Disorders,Affective Disorder, Psychotic,Affective Psychoses,Disorder, Psychotic Affective,Disorders, Psychotic Affective,Mood Disorder, Psychotic,Psychotic Affective Disorder,Psychotic Mood Disorder

Related Publications

J C Ballenger
January 1994, Psychiatria polska,
J C Ballenger
March 1985, East African medical journal,
J C Ballenger
February 1990, The British journal of psychiatry : the journal of mental science,
J C Ballenger
July 1986, Drug and therapeutics bulletin,
J C Ballenger
November 1984, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
J C Ballenger
December 2005, Expert opinion on pharmacotherapy,
Copied contents to your clipboard!